An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Metastatic Hormone-sensitive Prostate Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 168 (final count)
- Started
- Jul 7, 2025
- Main results expected
- Mar 15, 2032
- Fully finished
- Oct 4, 2035
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Prostate Specific Antigen 90 (PSA90) Rate
Measured over: From date of randomization till 30 days safety fup, assessed up to approximately 75 months
Incidence rate of adverse events (AEs)
Measured over: From date of randomization till 30 days safety fup, assessed up to approximately 75 months
Number of participants with dose adjustments
Measured over: From date of randomization till 30 days safety fup, assessed up to approximately 75 months
Duration of exposure to study treatment
Measured over: From date of randomization till 30 days safety fup, assessed up to approximately 75 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06991556 · record last updated 2026-10-19 · checked 2026-11-09 15:47 UTC